Teva to Buy Cephalon for $6.2 Billion

after it had been rejected by Johnson & Johnson and Upjohn, a U.S. drugmaker later bought by Pfizer. One of the first therapies for multiple sclerosis, the 14-year-old injected drug now has sales of about $3 billion a year. Teva estimates the deal will...